Interleukin-1β and tumor necrosis factor (TNF)-α sensitize human thyroid epithelial cells to TNF-related apoptosis-inducing ligand-induced apoptosis through increases in procaspase-7 and bid, and the down-regulation of p44/42 mitogen-activated protein kinase activity

被引:24
作者
Mezosi, E
Wang, SH
Utsugi, S
Bajnok, L
Bretz, JD
Gauger, PG
Thompson, NW
Baker, JR
机构
[1] Univ Michigan, Med Ctr, Ctr Biol Nanotechnol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Med Ctr, Dept Physiol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Med Ctr, Dept Surg, Ann Arbor, MI 48109 USA
关键词
D O I
10.1210/jc.2003-030697
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary thyroid cells are resistant to TNF-related apoptosis-inducing ligand ( TRAIL). Previously we showed that the combination of IL-1beta and TNFalpha facilitated TRAIL-mediated apoptosis in these cells and enhanced cell surface expression of TRAIL receptors. The aim of this study was to further characterize the mechanism by which these cytokines sensitized primary thyroid cells to TRAIL-mediated apoptosis. IL-1beta and TNFalpha increased the concentrations of procaspase-7 and Bid. In contrast, the p44/42 MAPK (Erk) pathway was active in thyroid cells and this activity was significantly decreased after exposure to IL-1beta/TNFalpha. A MAPK kinase inhibitor ( U0126) could enhance the cytokine-induced sensitization of thyroid cells to TRAIL, reinforcing the inhibitory role of Erk on TRAIL signaling. In conclusion, IL-1beta/ TNFalpha treatment sensitizes human thyroid cells to TRAIL-mediated apoptosis through increased surface expression of TRAIL receptors, increased expression of procaspase-7 and Bid, and the inhibition of p44/42 MAPK (Erk) pathway.
引用
收藏
页码:250 / 257
页数:8
相关论文
共 51 条
[11]   Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice [J].
Cretney, E ;
Takeda, K ;
Yagita, H ;
Glaccum, M ;
Peschon, JJ ;
Smyth, MJ .
JOURNAL OF IMMUNOLOGY, 2002, 168 (03) :1356-1361
[12]   Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family [J].
DegliEsposti, MA ;
Smolak, PJ ;
Walczak, H ;
Waugh, J ;
Huang, CP ;
DuBose, RF ;
Goodwin, RG ;
Smith, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1165-1170
[13]   TRAIL-induced apoptosis requires Bax-dependent mitochondria release of Smac/DIABLO [J].
Deng, YB ;
Lin, YH ;
Wu, XW .
GENES & DEVELOPMENT, 2002, 16 (01) :33-45
[14]   Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL [J].
Emery, JG ;
McDonnell, P ;
Burke, MB ;
Deen, KC ;
Lyn, S ;
Silverman, C ;
Dul, E ;
Appelbaum, ER ;
Eichman, C ;
DiPrinzio, R ;
Dodds, RA ;
James, IE ;
Rosenberg, M ;
Lee, JC ;
Young, PR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) :14363-14367
[15]  
GOLSTEIN P, 1997, CURR BIOL, V7, P750
[16]   TRAIL: a molecule with multiple receptors and control mechanisms [J].
Griffith, TS ;
Lynch, DH .
CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (05) :559-563
[17]   Cancer research - How TRAIL kills cancer cells, but not normal cells [J].
Gura, T .
SCIENCE, 1997, 277 (5327) :768-768
[18]   MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly [J].
Holmström, TH ;
Schmitz, I ;
Söderström, TS ;
Poukkula, M ;
Johnson, VL ;
Chow, SC ;
Krammer, PH ;
Eriksson, JE .
EMBO JOURNAL, 2000, 19 (20) :5418-5428
[19]   Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-κB and JNK activation and apoptosis through distinct pathways [J].
Hu, WH ;
Johnson, H ;
Shu, HB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (43) :30603-30610
[20]  
Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687